Plasma levels of enterolactone and percentage mammographic density among postmenopausal women

Cancer Epidemiology Biomarkers and Prevention

Volumn 14, Issue 9, 2005, Pages 2154-2159

  Stuedal, Anne ^a   Gram, Inger Torhild ^b   Bremnes, Yngve ^b   Adlercreutz, Herman ^c   Veierød, Marit B ^a   Ursin, Giske ^a,d  

^a UNIVERSITY OF OSLO   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

^c UNIVERSITY OF HELSINKI   (Finland)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; ENTEROLACTONE;

ADULT; AGED; ANTHROPOMETRY; ARTICLE; BODY MASS; BREAST CANCER; CANCER RISK; CARCINOGENESIS; COMPUTER ANALYSIS; CONTROLLED STUDY; CORRELATION COEFFICIENT; FEMALE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MULTIPLE REGRESSION; NORWAY; POSTMENOPAUSE; PREGNANCY; PRIORITY JOURNAL; REPRODUCTION; STATISTICAL MODEL;

4-BUTYROLACTONE; AGED; BIOLOGICAL MARKERS; BODY MASS INDEX; BREAST NEOPLASMS; COHORT STUDIES; FEMALE; HUMANS; LIGNANS; MAMMOGRAPHY; MIDDLE AGED; POSTMENOPAUSE;

EID: 27744570471     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-05-0116     Document Type: Article

References (63)

1. Johns PC, Yaffe MJ. X-ray characterisation of normal and neoplastic breast tissues. Phys Med Biol 1987;32:675-95.
2. Boyd NF, Lockwood GA, Byng JW, Tritchler DL, Yaffe MJ. Mammographic densities and breast cancer risk. Cancer Epidemiol Biomarkers Prev 1998;7:1133-44.
3. Byrne C, Schairer C, Wolfe J, et al. Mammographic features and breast cancer risk: effects with time, age, and menopause status. J Natl Cancer Inst 1995;87:1622-9.
4. Ursin G, Ma H, Wu AH, et al. Mammographic density and breast cancer in three ethnic groups. Cancer Epidemiol Biomarkers Prev 2003;12:332-8.
5. Ursin G, Spicer DV, Pike MC. Tamoxifen and prevention. Lancet 1993;341:693-4.
6. Brisson J, Brisson B, Cote G, Maunsell E, Beruhe S, Robert J. Tamoxifen and mammographic breast densities. Cancer Epidemiol Biomarkers Prev 2000;9:911-5.
7. Boyd N, Martin L, Stone J, Little L, Minkin S, Yaffe M. A longitudinal study of the effects of menopause on mammographic features. Cancer Epidemiol Biomarkers Prev 2002;11:1048-53.
8. Greendale GA, Reboussin BA, Slone S, Wasilauskas C, Pike MC, Ursin G. Postmenopausal hormone therapy and change in mammographic density. J Natl Cancer Inst 2003;95:30-7.
9. Rutter CM, Mandelson MT, Laya MB, Seger DJ, Taplin S. Changes in breast density associated with initiation, discontinuation, and continuing use of hormone replacement therapy. JAMA 2001;285:171-6.
10. Adlercreutz H. Phyto-oestrogens and cancer. Lancet Oncol 2002;3:364-73.
11. Bordello SP, Setchell KD, Axelson M, Lawson AM. Production and metabolism of lignans by the human faecal flora. J Appl Bacteriol 1985;58:37-43.
12. Adlercreutz H, Fotsis T, Lampe J, et al. Quantitative determination of lignans and isoflavonoids in plasma of omnivorous and vegetarian women by isotope dilution gas chromatography-mass spectrometry. Scand J Clin Lab Invest Suppl 1993;215:5-18.
13. Kurzer MS, Xu X. Dietary phytoestrogens. Annu Rev Nutr 1997;17:353-81.
14. Mazur W. Phytoestrogen content in foods. Baillieres Clin Endocrinol Metab 1998;12:729-42.
15. McCann SE, Muti P, Vito D, Edge SB, Trevisan M, Freudenheim JL. Dietary lignan intakes and risk of pre- and postmenopausal breast cancer. Int J Cancer 2004;111:440-3.
16. McCann SE, Moysich KB, Freudenheim JL, Ambrosone CB, Shields PG. The risk of breast cancer associated with dietary lignans differs by CYP17 genotype in women. J Nutr 2002;132:3036-41.
17. Horn-Ross PL, Hoggatt KJ, West DW, et al. Recent diet and breast cancer risk: the California Teachers Study (USA). Cancer Causes Control 2002;13:407-15.
18. Linseisen J, Piller R, Hermann S, Chang-Claude J. Dietary phytoestrogen intake and premenopausal breast cancer risk in a German case-control study. Int J Cancer 2004;110:284-90.
19. Keinan-Boker L, Der Schouw YT, Grobbee DE, Peeters PH. Dietary phytoestrogens and breast cancer risk. Am J Clin Nutr 2004;79:282-8.
20. denTonkelaar I, Keinan-Boker L, Veer PV, et al. Urinary phytoestrogens and postmenopausal breast cancer risk. Cancer Epidemiol Biomarkers Prev 2001;10:223-8.
21. Ingram D, Sanders K, Kolybaba M, Lopez D. Case-control study of phyto-oestrogens and breast cancer. Lancet 1997;350:990-4.
22. Grace PB, Taylor JI, Low YL, et al. Phytoestrogen concentrations in serum and spot urine as biomarkers for dietary phytoestrogen intake and their relation to breast cancer risk in European Prospective Investigation of Cancer and Nutrition-Norfolk. Cancer Epidemiol Biomarkers Prev 2004;13:698-708.
23. Hulten K, Winkvist A, Lenner P, Johansson R, Adlercreutz H, Hallmans G. An incident case-referent study on plasma enterolactone and breast cancer risk. Eur J Nutr 2002;41:168-76.
24. Pietinen P, Stumpf K, Mannisto S, Kataja V, Uusitupa M, Adlercreutz H. Serum enterolactone and risk of breast cancer: a case-control study in eastern Finland. Cancer Epidemiol Biomarkers Prev 2001;10:339-44.
25. Kilkkinen A, Virtamo J, Vartiainen E, et al. Serum enterolactone concentration is not associated with breast cancer risk in a nested case-control study. Int J Cancer 2004;108:277-80.
26. Zeleniuch-Jacquotte A, Adlercreutz H, Shore RE, et al. Circulating enterolactone and risk of breast cancer: a prospective study in New York. Br J Cancer 2004;91:99-105.
27. Olsen A, Knudsen KE, Thomsen BL, et al. Plasma enterolactone and breast cancer incidence by estrogen receptor status. Cancer Epidemiol Biomarkers Prev 2004;13:2084-9.
28. Mazur WM, Uehara M, Wahala K, Adlercreutz H. Phyto-oestrogen content of berries, and plasma concentrations and urinary excretion of enterolactone after a single strawberry-meal in human subjects. Br J Nutr 2000;83:381-7.
29. Heinonen S, Nurmi T, Liukkonen K, et al. In vitro metabolism of plant lignans: new precursors of mammalian lignans enterolactone and enterodiol. J Agric Food Chem 2001;49:3178-86.
30. Horner NK, Kristal AR, Prunty J, Skor HE, Potter JD, Lampe JW. Dietary determinants of plasma enterolactone. Cancer Epidemiol Biomarkers Prev 2002;11:121-6.
31. Kilkkinen A, Stumpf K, Pietinen P, Valsta LM, Tapanainen H, Adlercreutz H. Determinants of serum enterolactone concentration. Am J Clin Nutr 2001;73:1094-100.
32. Harvey JA, Pinkerton JV, Herman CR. Short-term cessation of hormone replacement therapy and improvement of mammographic specificity. J Natl Cancer Inst 1997;89:1623-5.
33. Ursin G, Parisky YR, Pike MC, Spicer DV. Mammographic density changes during the menstrual cycle. Cancer Epidemiol Biomarkers Prev 2001;10:141-2.
34. Dai Q, Franke AA, Jin F, et al. Urinary excretion of phytoestrogens and risk of breast cancer among Chinese women in Shanghai. Cancer Epidemiol Biomarkers Prev 2002;11:815-21.
35. Shu XO, Jin F, Dai Q, et al. Soyfood intake during adolescence and subsequent risk of breast cancer among Chinese women. Cancer Epidemiol Biomarkers Prev 2001;10:483-8.
36. Yamamoto S, Sobue T, Kobayashi M, Sasaki S, Tsugane S. Soy, isoflavones, and breast cancer risk in Japan. J Natl Cancer Inst 2003;95:906-13.
37. Jakes RW, Duffy SW, Ng FC, et al. Mammographic parenchymal patterns and self-reported soy intake in Singapore Chinese women. Cancer Epidemiol Biomarkers Prev 2002;11:608-13.
38. Maskarinec G, Meng L. An investigation of soy intake and mammographic characteristics in Hawaii. Breast Cancer Res 2001;3:134-41.
39. Maskarinec G, Williams AE, Carlin L. Mammographic densities in a one-year isoflavone intervention. Eur J Cancer Prev 2003;12:165-9.
40. Atkinson C, Warren R. Effects of isoflavones on breast density, estradiol and gonadotrophins: a double-blind, randomized, placebo-controlled trial. J Nutr 2003;132:s577.
41. Gram IT, Bremnes Y, Ursin G, Maskarinec G, Bjurstam N, Lund E. Percent density, Wolfe and Tabar mamographic patterns-agreement and association with breast cancer risk factors. Breast Cancer Res 2005;7:R854-61.
42. Adlercreutz H, Wang GJ, Lapcik O, et al. Time-resolved fluoroimmunoassay for plasma enterolactone. Anal Biochem 1998;265:208-15.
43. Stumpf K, Uehara M, Nurmi T, Adlercreutz H. Changes in the time-resolved fluoroimmunoassay of plasma enterolactone. Anal Biochem 2000;284:153-7.
44. Ursin G, Astrahan MA, Salane M, et al. The detection of changes in mammographic densities. Cancer Epidemiol Biomarkers Prev 1998;7:43-7.
45. Adlercreutz H, Fotsis T, Heikkinen R, et al. Excretion of the lignans enterolactone and enterodiol and of equol in omnivorous and vegetarian postmenopausal women and in women with breast cancer. Lancet 1982;2:1295-9.
46. Boccardo F, Lunardi G, Guglielmini P, et al. Serum enterolactone levels and the risk of breast cancer in women with palpable cysts. Eur J Cancer 2004;40:84-9.
47. Sathyamoorthy N, Wang TT, Phang JM. Stimulation of pS2 expression by diet-derived compounds. Cancer Res 1994;54:957-61.
48. Mousavi Y, Adlercreutz H. Enterolactone and estradiol inhibit each other's proliferative effect on MCF-7 breast cancer cells in culture. J Steroid Biochem Mol Biol 1992;41:615-9.
49. Wang C, Makela T, Hase T, Adlercreutz H, Kurzer MS. Lignans and flavonoids inhibit aromatase enzyme in human preadipocytes. J Steroid Biochem Mol Biol 1994;50:205-12.
50. Adlercreutz H, Bannwart C, Wahala K, et al. Inhibition of human aromatase by mammalian lignans and isoflavonoid phytoestrogens. J Steroid Biochem Mol Biol 1993;44:147-53.
51. Adlercreutz H, Mousavi Y, Clark J, et al. Dietary phytoestrogens and cancer: in vitro and in vivo studies. J Steroid Biochem Mol Biol 1992;41:331-7.
52. Martin ME, Haourigui M, Pelissero C, Benassayag C, Nunez EA. Interactions between phytoestrogens and human sex steroid binding protein. Life Sci 1996;58:429-36.
53. Lee HP, Gourley L, Duffy SW, Esteve J, Lee J, Day NE. Risk factors for breast cancer by age and menopausal status: a case-control study in Singapore. Cancer Causes Control 1992;3:313-22.
54. Hirose K, Tajima K, Hamajima N, et al. A large-scale, hospital-based case-control study of risk factors of breast cancer according to menopausal status. Jpn J Cancer Res 1995;86:146-54.
55. Hutchins AM, Martini MC, Olson BA, Thomas W, Slavin JL. Flaxseed consumption influences endogenous hormone concentrations in postmenopausal women. Nutr Cancer 2001;39:58-65.
56. Brooks JD, Ward WE, Lewis JE, et al. Supplementation with flaxseed alters estrogen metabolism in postmenopausal women to a greater extent than does supplementation with an equal amount of soy. Am J Clin Nutr 2004;79:318-25.
57. Phipps WR, Martini MC, Lampe JW, Slavin JL, Kurzer MS. Effect of flax seed ingestion on the menstrual cycle. J Clin Endocrinol Metab 1993;77:1215-9.
58. Frische EJ, Hutchins AM, Martini MC, Thomas W, Slavin JL. Effect of flaxseed and wheat bran on serum hormones and lignan excretion in premenopausal women. J Am Coll Nutr 2003;22:550-4.
59. Stumpf K, Adlercreutz H. Short-term variations in enterolactone in serum, 24-hour urine, and spot urine and relationship with enterolactone concentrations. Clin Chem 2003;49:178-81.
60. Zeleniuch-Jacquotte A, Adlercreutz H, Akhmedkhanov A, Toniolo P. Reliability of serum measurements of lignans and isoflavonoid phytoestrogens over a two-year period. Cancer Epidemiol Biomarkers Prev 1998;7:885-9.
61. Hausner H, Johnsen NF, Hallund J, Tetens I. A single measurement is inadequate to estimate enterolactone levels in Danish postmenopausal women due to large intraindividual variation. J Nutr 2004;134:1197-200.
62. Kilkkinen A, Pietinen P, Klaukka T, Virtamo J, Korhonen P, Adlercreutz H. Use of oral antimicrobials decreases serum enterolactone concentration. Am J Epidemiol 2002;155:472-7.
63. Boccardo F, Lunardi GL, Petti AR, Rubagotti A. Enterolactone in breast cyst fluid: correlation with EGF and breast cancer risk. Breast Cancer Res Treat 2003;79:17-23.